The U.S. Food and Drug Administration approved Novartis's oral Bruton’s tyrosine kinase inhibitor, remibrutinib (branded as Rhapsido), as a second-line treatment for chronic spontaneous urticaria (CSU). This marks the first oral BTK inhibitor approved for this rare inflammatory skin condition. The therapy inhibits the release of histamine and proinflammatory mediators. Clinical trials are ongoing to explore potential applications in other immune-mediated disorders.